nodes	percent_of_prediction	percent_of_DWPC	metapath
Dalfampridine—KCNC2—prostate gland—urinary bladder cancer	0.0245	0.0438	CbGeAlD
Dalfampridine—KCNG1—prostate gland—urinary bladder cancer	0.0218	0.039	CbGeAlD
Dalfampridine—KCNV1—renal system—urinary bladder cancer	0.0185	0.033	CbGeAlD
Dalfampridine—KCNC4—prostate gland—urinary bladder cancer	0.0182	0.0325	CbGeAlD
Dalfampridine—KCNQ4—prostate gland—urinary bladder cancer	0.0175	0.0312	CbGeAlD
Dalfampridine—KCNQ5—prostate gland—urinary bladder cancer	0.017	0.0303	CbGeAlD
Dalfampridine—KCNS1—seminal vesicle—urinary bladder cancer	0.0161	0.0287	CbGeAlD
Dalfampridine—KCNS2—female reproductive system—urinary bladder cancer	0.0157	0.0281	CbGeAlD
Dalfampridine—KCNB1—epithelium—urinary bladder cancer	0.0155	0.0278	CbGeAlD
Dalfampridine—KCNC3—epithelium—urinary bladder cancer	0.0151	0.0269	CbGeAlD
Dalfampridine—KCNB1—smooth muscle tissue—urinary bladder cancer	0.015	0.0267	CbGeAlD
Dalfampridine—KCNS1—epithelium—urinary bladder cancer	0.014	0.0249	CbGeAlD
Dalfampridine—KCNA5—prostate gland—urinary bladder cancer	0.0139	0.0249	CbGeAlD
Dalfampridine—KCNS3—prostate gland—urinary bladder cancer	0.0136	0.0243	CbGeAlD
Dalfampridine—KCNF1—seminal vesicle—urinary bladder cancer	0.0132	0.0235	CbGeAlD
Dalfampridine—KCNH6—prostate gland—urinary bladder cancer	0.0124	0.0222	CbGeAlD
Dalfampridine—KCNS3—seminal vesicle—urinary bladder cancer	0.0115	0.0206	CbGeAlD
Dalfampridine—KCNG1—vagina—urinary bladder cancer	0.0108	0.0193	CbGeAlD
Dalfampridine—KCND3—prostate gland—urinary bladder cancer	0.0104	0.0185	CbGeAlD
Dalfampridine—KCNQ1—prostate gland—urinary bladder cancer	0.01	0.0179	CbGeAlD
Dalfampridine—KCNS3—epithelium—urinary bladder cancer	0.01	0.0179	CbGeAlD
Dalfampridine—KCND1—female reproductive system—urinary bladder cancer	0.00992	0.0177	CbGeAlD
Dalfampridine—KCNA5—smooth muscle tissue—urinary bladder cancer	0.00985	0.0176	CbGeAlD
Dalfampridine—KCNA5—renal system—urinary bladder cancer	0.00949	0.0169	CbGeAlD
Dalfampridine—KCNS1—vagina—urinary bladder cancer	0.00938	0.0168	CbGeAlD
Dalfampridine—KCNS3—renal system—urinary bladder cancer	0.00929	0.0166	CbGeAlD
Dalfampridine—KCNQ5—female reproductive system—urinary bladder cancer	0.00927	0.0166	CbGeAlD
Dalfampridine—KCNS3—urethra—urinary bladder cancer	0.00912	0.0163	CbGeAlD
Dalfampridine—KCND1—vagina—urinary bladder cancer	0.00897	0.016	CbGeAlD
Dalfampridine—KCNQ1—seminal vesicle—urinary bladder cancer	0.00848	0.0151	CbGeAlD
Dalfampridine—KCNH6—renal system—urinary bladder cancer	0.00848	0.0151	CbGeAlD
Dalfampridine—KCNQ5—vagina—urinary bladder cancer	0.00838	0.015	CbGeAlD
Dalfampridine—CYP2E1—urine—urinary bladder cancer	0.0082	0.0146	CbGeAlD
Dalfampridine—KCNF1—vagina—urinary bladder cancer	0.00768	0.0137	CbGeAlD
Dalfampridine—KCNA5—female reproductive system—urinary bladder cancer	0.0076	0.0136	CbGeAlD
Dalfampridine—KCNQ3—female reproductive system—urinary bladder cancer	0.00744	0.0133	CbGeAlD
Dalfampridine—KCNA5—vagina—urinary bladder cancer	0.00687	0.0123	CbGeAlD
Dalfampridine—KCNQ2—female reproductive system—urinary bladder cancer	0.00685	0.0122	CbGeAlD
Dalfampridine—KCNQ1—renal system—urinary bladder cancer	0.00683	0.0122	CbGeAlD
Dalfampridine—KCNH6—female reproductive system—urinary bladder cancer	0.00679	0.0121	CbGeAlD
Dalfampridine—KCNS3—vagina—urinary bladder cancer	0.00673	0.012	CbGeAlD
Dalfampridine—KCNQ1—urethra—urinary bladder cancer	0.00671	0.012	CbGeAlD
Dalfampridine—KCNA3—lymph node—urinary bladder cancer	0.00638	0.0114	CbGeAlD
Dalfampridine—KCNA2—lymph node—urinary bladder cancer	0.00607	0.0108	CbGeAlD
Dalfampridine—KCNC4—lymph node—urinary bladder cancer	0.0058	0.0104	CbGeAlD
Dalfampridine—KCNQ1—female reproductive system—urinary bladder cancer	0.00547	0.00978	CbGeAlD
Dalfampridine—KCNQ5—lymph node—urinary bladder cancer	0.00542	0.00969	CbGeAlD
Dalfampridine—Chest discomfort—Etoposide—urinary bladder cancer	0.00465	0.0117	CcSEcCtD
Dalfampridine—KCNA5—lymph node—urinary bladder cancer	0.00444	0.00794	CbGeAlD
Dalfampridine—KCNS3—lymph node—urinary bladder cancer	0.00435	0.00777	CbGeAlD
Dalfampridine—Asthenia—Valrubicin—urinary bladder cancer	0.00424	0.0107	CcSEcCtD
Dalfampridine—Confusional state—Mitomycin—urinary bladder cancer	0.0041	0.0103	CcSEcCtD
Dalfampridine—Dizziness—Valrubicin—urinary bladder cancer	0.0039	0.00983	CcSEcCtD
Dalfampridine—KCNH2—prostate gland—urinary bladder cancer	0.00382	0.00683	CbGeAlD
Dalfampridine—Vomiting—Valrubicin—urinary bladder cancer	0.00375	0.00945	CcSEcCtD
Dalfampridine—Rash—Valrubicin—urinary bladder cancer	0.00372	0.00937	CcSEcCtD
Dalfampridine—Dermatitis—Valrubicin—urinary bladder cancer	0.00372	0.00936	CcSEcCtD
Dalfampridine—Headache—Valrubicin—urinary bladder cancer	0.0037	0.00931	CcSEcCtD
Dalfampridine—Dyspnoea—Mitomycin—urinary bladder cancer	0.00363	0.00913	CcSEcCtD
Dalfampridine—Nausea—Valrubicin—urinary bladder cancer	0.00351	0.00883	CcSEcCtD
Dalfampridine—Feeling abnormal—Mitomycin—urinary bladder cancer	0.00335	0.00844	CcSEcCtD
Dalfampridine—KCND3—lymph node—urinary bladder cancer	0.00331	0.00591	CbGeAlD
Dalfampridine—KCNH2—seminal vesicle—urinary bladder cancer	0.00323	0.00578	CbGeAlD
Dalfampridine—Infestation NOS—Thiotepa—urinary bladder cancer	0.00321	0.00808	CcSEcCtD
Dalfampridine—Infestation—Thiotepa—urinary bladder cancer	0.00321	0.00808	CcSEcCtD
Dalfampridine—KCNQ1—lymph node—urinary bladder cancer	0.0032	0.00572	CbGeAlD
Dalfampridine—Nasopharyngitis—Fluorouracil—urinary bladder cancer	0.00308	0.00775	CcSEcCtD
Dalfampridine—CYP2E1—prostate gland—urinary bladder cancer	0.00294	0.00526	CbGeAlD
Dalfampridine—Asthenia—Mitomycin—urinary bladder cancer	0.00292	0.00735	CcSEcCtD
Dalfampridine—Nasopharyngitis—Cisplatin—urinary bladder cancer	0.00292	0.00735	CcSEcCtD
Dalfampridine—Connective tissue disorder—Thiotepa—urinary bladder cancer	0.00283	0.00712	CcSEcCtD
Dalfampridine—Dizziness—Mitomycin—urinary bladder cancer	0.00269	0.00677	CcSEcCtD
Dalfampridine—Infestation—Fluorouracil—urinary bladder cancer	0.00265	0.00668	CcSEcCtD
Dalfampridine—Infestation NOS—Fluorouracil—urinary bladder cancer	0.00265	0.00668	CcSEcCtD
Dalfampridine—Angiopathy—Thiotepa—urinary bladder cancer	0.00261	0.00658	CcSEcCtD
Dalfampridine—KCNH2—renal system—urinary bladder cancer	0.00261	0.00465	CbGeAlD
Dalfampridine—Immune system disorder—Thiotepa—urinary bladder cancer	0.0026	0.00655	CcSEcCtD
Dalfampridine—Mediastinal disorder—Thiotepa—urinary bladder cancer	0.00259	0.00653	CcSEcCtD
Dalfampridine—Vomiting—Mitomycin—urinary bladder cancer	0.00259	0.00651	CcSEcCtD
Dalfampridine—Urinary tract infection—Fluorouracil—urinary bladder cancer	0.00258	0.00649	CcSEcCtD
Dalfampridine—Rash—Mitomycin—urinary bladder cancer	0.00256	0.00646	CcSEcCtD
Dalfampridine—Dermatitis—Mitomycin—urinary bladder cancer	0.00256	0.00645	CcSEcCtD
Dalfampridine—KCNH2—urethra—urinary bladder cancer	0.00256	0.00457	CbGeAlD
Dalfampridine—Headache—Mitomycin—urinary bladder cancer	0.00255	0.00642	CcSEcCtD
Dalfampridine—Mental disorder—Thiotepa—urinary bladder cancer	0.00252	0.00635	CcSEcCtD
Dalfampridine—CYP2E1—seminal vesicle—urinary bladder cancer	0.00249	0.00445	CbGeAlD
Dalfampridine—Back pain—Thiotepa—urinary bladder cancer	0.00242	0.0061	CcSEcCtD
Dalfampridine—Nausea—Mitomycin—urinary bladder cancer	0.00242	0.00608	CcSEcCtD
Dalfampridine—Connective tissue disorder—Gemcitabine—urinary bladder cancer	0.00238	0.00599	CcSEcCtD
Dalfampridine—Infestation—Etoposide—urinary bladder cancer	0.0023	0.0058	CcSEcCtD
Dalfampridine—Infestation NOS—Etoposide—urinary bladder cancer	0.0023	0.0058	CcSEcCtD
Dalfampridine—Connective tissue disorder—Cisplatin—urinary bladder cancer	0.00222	0.00559	CcSEcCtD
Dalfampridine—Angiopathy—Gemcitabine—urinary bladder cancer	0.0022	0.00553	CcSEcCtD
Dalfampridine—Immune system disorder—Gemcitabine—urinary bladder cancer	0.00219	0.00551	CcSEcCtD
Dalfampridine—Mediastinal disorder—Gemcitabine—urinary bladder cancer	0.00218	0.0055	CcSEcCtD
Dalfampridine—Convulsion—Thiotepa—urinary bladder cancer	0.00217	0.00547	CcSEcCtD
Dalfampridine—Anxiety—Thiotepa—urinary bladder cancer	0.00213	0.00535	CcSEcCtD
Dalfampridine—Unspecified disorder of skin and subcutaneous tissue—Thiotepa—urinary bladder cancer	0.00212	0.00534	CcSEcCtD
Dalfampridine—KCNH2—female reproductive system—urinary bladder cancer	0.00209	0.00373	CbGeAlD
Dalfampridine—Confusional state—Thiotepa—urinary bladder cancer	0.00206	0.00519	CcSEcCtD
Dalfampridine—Back pain—Gemcitabine—urinary bladder cancer	0.00204	0.00514	CcSEcCtD
Dalfampridine—Immune system disorder—Cisplatin—urinary bladder cancer	0.00204	0.00513	CcSEcCtD
Dalfampridine—Mediastinal disorder—Cisplatin—urinary bladder cancer	0.00203	0.00512	CcSEcCtD
Dalfampridine—Infection—Thiotepa—urinary bladder cancer	0.00203	0.00512	CcSEcCtD
Dalfampridine—CYP2E1—renal system—urinary bladder cancer	0.00201	0.00358	CbGeAlD
Dalfampridine—Nervous system disorder—Thiotepa—urinary bladder cancer	0.00201	0.00505	CcSEcCtD
Dalfampridine—Skin disorder—Thiotepa—urinary bladder cancer	0.00199	0.005	CcSEcCtD
Dalfampridine—CYP2E1—urethra—urinary bladder cancer	0.00197	0.00352	CbGeAlD
Dalfampridine—KCNH2—vagina—urinary bladder cancer	0.00189	0.00337	CbGeAlD
Dalfampridine—Angiopathy—Etoposide—urinary bladder cancer	0.00188	0.00472	CcSEcCtD
Dalfampridine—Immune system disorder—Etoposide—urinary bladder cancer	0.00187	0.0047	CcSEcCtD
Dalfampridine—Mediastinal disorder—Etoposide—urinary bladder cancer	0.00186	0.00469	CcSEcCtD
Dalfampridine—Tremor—Cisplatin—urinary bladder cancer	0.00184	0.00464	CcSEcCtD
Dalfampridine—Paraesthesia—Thiotepa—urinary bladder cancer	0.00184	0.00462	CcSEcCtD
Dalfampridine—Dyspepsia—Thiotepa—urinary bladder cancer	0.0018	0.00453	CcSEcCtD
Dalfampridine—Convulsion—Fluorouracil—urinary bladder cancer	0.0018	0.00452	CcSEcCtD
Dalfampridine—Chest pain—Gemcitabine—urinary bladder cancer	0.00179	0.00452	CcSEcCtD
Dalfampridine—Unspecified disorder of skin and subcutaneous tissue—Gemcitabine—urinary bladder cancer	0.00178	0.00449	CcSEcCtD
Dalfampridine—Gastrointestinal disorder—Thiotepa—urinary bladder cancer	0.00177	0.00445	CcSEcCtD
Dalfampridine—Chest pain—Fluorouracil—urinary bladder cancer	0.00176	0.00444	CcSEcCtD
Dalfampridine—Constipation—Thiotepa—urinary bladder cancer	0.00175	0.0044	CcSEcCtD
Dalfampridine—Back pain—Etoposide—urinary bladder cancer	0.00174	0.00438	CcSEcCtD
Dalfampridine—Anaphylactic shock—Gemcitabine—urinary bladder cancer	0.00172	0.00433	CcSEcCtD
Dalfampridine—Infection—Gemcitabine—urinary bladder cancer	0.00171	0.0043	CcSEcCtD
Dalfampridine—Confusional state—Fluorouracil—urinary bladder cancer	0.00171	0.0043	CcSEcCtD
Dalfampridine—Convulsion—Cisplatin—urinary bladder cancer	0.0017	0.00429	CcSEcCtD
Dalfampridine—Anaphylactic shock—Fluorouracil—urinary bladder cancer	0.00169	0.00426	CcSEcCtD
Dalfampridine—Nervous system disorder—Gemcitabine—urinary bladder cancer	0.00169	0.00425	CcSEcCtD
Dalfampridine—Feeling abnormal—Thiotepa—urinary bladder cancer	0.00169	0.00424	CcSEcCtD
Dalfampridine—Infection—Fluorouracil—urinary bladder cancer	0.00168	0.00423	CcSEcCtD
Dalfampridine—Skin disorder—Gemcitabine—urinary bladder cancer	0.00167	0.00421	CcSEcCtD
Dalfampridine—Anxiety—Cisplatin—urinary bladder cancer	0.00167	0.0042	CcSEcCtD
Dalfampridine—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—urinary bladder cancer	0.00166	0.00418	CcSEcCtD
Dalfampridine—Nervous system disorder—Fluorouracil—urinary bladder cancer	0.00166	0.00418	CcSEcCtD
Dalfampridine—Urticaria—Thiotepa—urinary bladder cancer	0.00162	0.00409	CcSEcCtD
Dalfampridine—Hypotension—Gemcitabine—urinary bladder cancer	0.00161	0.00405	CcSEcCtD
Dalfampridine—CYP2E1—female reproductive system—urinary bladder cancer	0.00161	0.00287	CbGeAlD
Dalfampridine—Anaphylactic shock—Cisplatin—urinary bladder cancer	0.0016	0.00404	CcSEcCtD
Dalfampridine—Infection—Cisplatin—urinary bladder cancer	0.00159	0.00401	CcSEcCtD
Dalfampridine—Hypotension—Fluorouracil—urinary bladder cancer	0.00158	0.00398	CcSEcCtD
Dalfampridine—Nervous system disorder—Cisplatin—urinary bladder cancer	0.00157	0.00396	CcSEcCtD
Dalfampridine—Convulsion—Etoposide—urinary bladder cancer	0.00156	0.00393	CcSEcCtD
Dalfampridine—Skin disorder—Cisplatin—urinary bladder cancer	0.00156	0.00392	CcSEcCtD
Dalfampridine—Insomnia—Gemcitabine—urinary bladder cancer	0.00156	0.00392	CcSEcCtD
Dalfampridine—Paraesthesia—Gemcitabine—urinary bladder cancer	0.00154	0.00389	CcSEcCtD
Dalfampridine—Dyspnoea—Gemcitabine—urinary bladder cancer	0.00153	0.00386	CcSEcCtD
Dalfampridine—Chest pain—Etoposide—urinary bladder cancer	0.00153	0.00386	CcSEcCtD
Dalfampridine—Insomnia—Fluorouracil—urinary bladder cancer	0.00153	0.00385	CcSEcCtD
Dalfampridine—Unspecified disorder of skin and subcutaneous tissue—Etoposide—urinary bladder cancer	0.00152	0.00383	CcSEcCtD
Dalfampridine—Paraesthesia—Fluorouracil—urinary bladder cancer	0.00152	0.00383	CcSEcCtD
Dalfampridine—Dyspnoea—Fluorouracil—urinary bladder cancer	0.00151	0.0038	CcSEcCtD
Dalfampridine—Hypersensitivity—Thiotepa—urinary bladder cancer	0.00151	0.00379	CcSEcCtD
Dalfampridine—Hypotension—Cisplatin—urinary bladder cancer	0.0015	0.00377	CcSEcCtD
Dalfampridine—Nasopharyngitis—Epirubicin—urinary bladder cancer	0.0015	0.00377	CcSEcCtD
Dalfampridine—Dyspepsia—Fluorouracil—urinary bladder cancer	0.00149	0.00375	CcSEcCtD
Dalfampridine—Gastrointestinal disorder—Gemcitabine—urinary bladder cancer	0.00149	0.00374	CcSEcCtD
Dalfampridine—Confusional state—Etoposide—urinary bladder cancer	0.00148	0.00373	CcSEcCtD
Dalfampridine—Constipation—Gemcitabine—urinary bladder cancer	0.00147	0.0037	CcSEcCtD
Dalfampridine—Anaphylactic shock—Etoposide—urinary bladder cancer	0.00147	0.0037	CcSEcCtD
Dalfampridine—Asthenia—Thiotepa—urinary bladder cancer	0.00147	0.0037	CcSEcCtD
Dalfampridine—Gastrointestinal disorder—Fluorouracil—urinary bladder cancer	0.00146	0.00368	CcSEcCtD
Dalfampridine—Infection—Etoposide—urinary bladder cancer	0.00146	0.00368	CcSEcCtD
Dalfampridine—Paraesthesia—Cisplatin—urinary bladder cancer	0.00144	0.00363	CcSEcCtD
Dalfampridine—Dyspnoea—Cisplatin—urinary bladder cancer	0.00143	0.0036	CcSEcCtD
Dalfampridine—Skin disorder—Etoposide—urinary bladder cancer	0.00143	0.00359	CcSEcCtD
Dalfampridine—Feeling abnormal—Gemcitabine—urinary bladder cancer	0.00142	0.00357	CcSEcCtD
Dalfampridine—Feeling abnormal—Fluorouracil—urinary bladder cancer	0.00139	0.00351	CcSEcCtD
Dalfampridine—Nasopharyngitis—Doxorubicin—urinary bladder cancer	0.00139	0.00349	CcSEcCtD
Dalfampridine—Gastrointestinal disorder—Cisplatin—urinary bladder cancer	0.00138	0.00349	CcSEcCtD
Dalfampridine—Infestation NOS—Methotrexate—urinary bladder cancer	0.00138	0.00347	CcSEcCtD
Dalfampridine—Infestation—Methotrexate—urinary bladder cancer	0.00138	0.00347	CcSEcCtD
Dalfampridine—Hypotension—Etoposide—urinary bladder cancer	0.00137	0.00346	CcSEcCtD
Dalfampridine—Dizziness—Thiotepa—urinary bladder cancer	0.00135	0.00341	CcSEcCtD
Dalfampridine—Urticaria—Fluorouracil—urinary bladder cancer	0.00134	0.00338	CcSEcCtD
Dalfampridine—Feeling abnormal—Cisplatin—urinary bladder cancer	0.00132	0.00333	CcSEcCtD
Dalfampridine—Paraesthesia—Etoposide—urinary bladder cancer	0.00132	0.00332	CcSEcCtD
Dalfampridine—Dyspnoea—Etoposide—urinary bladder cancer	0.00131	0.0033	CcSEcCtD
Dalfampridine—Vomiting—Thiotepa—urinary bladder cancer	0.0013	0.00327	CcSEcCtD
Dalfampridine—Infestation NOS—Epirubicin—urinary bladder cancer	0.00129	0.00325	CcSEcCtD
Dalfampridine—Infestation—Epirubicin—urinary bladder cancer	0.00129	0.00325	CcSEcCtD
Dalfampridine—Rash—Thiotepa—urinary bladder cancer	0.00129	0.00325	CcSEcCtD
Dalfampridine—Dermatitis—Thiotepa—urinary bladder cancer	0.00129	0.00324	CcSEcCtD
Dalfampridine—Headache—Thiotepa—urinary bladder cancer	0.00128	0.00323	CcSEcCtD
Dalfampridine—Gastrointestinal disorder—Etoposide—urinary bladder cancer	0.00127	0.00319	CcSEcCtD
Dalfampridine—Constipation—Etoposide—urinary bladder cancer	0.00126	0.00316	CcSEcCtD
Dalfampridine—Urinary tract infection—Epirubicin—urinary bladder cancer	0.00126	0.00316	CcSEcCtD
Dalfampridine—Hypersensitivity—Fluorouracil—urinary bladder cancer	0.00125	0.00314	CcSEcCtD
Dalfampridine—Asthenia—Gemcitabine—urinary bladder cancer	0.00123	0.00311	CcSEcCtD
Dalfampridine—KCNH2—lymph node—urinary bladder cancer	0.00122	0.00218	CbGeAlD
Dalfampridine—Nausea—Thiotepa—urinary bladder cancer	0.00121	0.00306	CcSEcCtD
Dalfampridine—Feeling abnormal—Etoposide—urinary bladder cancer	0.00121	0.00305	CcSEcCtD
Dalfampridine—Infestation NOS—Doxorubicin—urinary bladder cancer	0.00119	0.00301	CcSEcCtD
Dalfampridine—Infestation—Doxorubicin—urinary bladder cancer	0.00119	0.00301	CcSEcCtD
Dalfampridine—Hypersensitivity—Cisplatin—urinary bladder cancer	0.00118	0.00298	CcSEcCtD
Dalfampridine—Urticaria—Etoposide—urinary bladder cancer	0.00117	0.00294	CcSEcCtD
Dalfampridine—Urinary tract infection—Doxorubicin—urinary bladder cancer	0.00116	0.00292	CcSEcCtD
Dalfampridine—Asthenia—Cisplatin—urinary bladder cancer	0.00115	0.0029	CcSEcCtD
Dalfampridine—Connective tissue disorder—Epirubicin—urinary bladder cancer	0.00114	0.00287	CcSEcCtD
Dalfampridine—Angiopathy—Methotrexate—urinary bladder cancer	0.00112	0.00283	CcSEcCtD
Dalfampridine—Immune system disorder—Methotrexate—urinary bladder cancer	0.00112	0.00282	CcSEcCtD
Dalfampridine—Dizziness—Fluorouracil—urinary bladder cancer	0.00112	0.00282	CcSEcCtD
Dalfampridine—Mediastinal disorder—Methotrexate—urinary bladder cancer	0.00112	0.00281	CcSEcCtD
Dalfampridine—Vomiting—Gemcitabine—urinary bladder cancer	0.00109	0.00275	CcSEcCtD
Dalfampridine—Mental disorder—Methotrexate—urinary bladder cancer	0.00109	0.00273	CcSEcCtD
Dalfampridine—Rash—Gemcitabine—urinary bladder cancer	0.00108	0.00273	CcSEcCtD
Dalfampridine—Dermatitis—Gemcitabine—urinary bladder cancer	0.00108	0.00273	CcSEcCtD
Dalfampridine—Hypersensitivity—Etoposide—urinary bladder cancer	0.00108	0.00273	CcSEcCtD
Dalfampridine—Headache—Gemcitabine—urinary bladder cancer	0.00108	0.00271	CcSEcCtD
Dalfampridine—Vomiting—Fluorouracil—urinary bladder cancer	0.00108	0.00271	CcSEcCtD
Dalfampridine—Rash—Fluorouracil—urinary bladder cancer	0.00107	0.00269	CcSEcCtD
Dalfampridine—Dermatitis—Fluorouracil—urinary bladder cancer	0.00107	0.00268	CcSEcCtD
Dalfampridine—Headache—Fluorouracil—urinary bladder cancer	0.00106	0.00267	CcSEcCtD
Dalfampridine—Asthenia—Etoposide—urinary bladder cancer	0.00105	0.00265	CcSEcCtD
Dalfampridine—Connective tissue disorder—Doxorubicin—urinary bladder cancer	0.00105	0.00265	CcSEcCtD
Dalfampridine—Angiopathy—Epirubicin—urinary bladder cancer	0.00105	0.00265	CcSEcCtD
Dalfampridine—Immune system disorder—Epirubicin—urinary bladder cancer	0.00105	0.00264	CcSEcCtD
Dalfampridine—Mediastinal disorder—Epirubicin—urinary bladder cancer	0.00104	0.00263	CcSEcCtD
Dalfampridine—Back pain—Methotrexate—urinary bladder cancer	0.00104	0.00263	CcSEcCtD
Dalfampridine—Nausea—Gemcitabine—urinary bladder cancer	0.00102	0.00257	CcSEcCtD
Dalfampridine—Vomiting—Cisplatin—urinary bladder cancer	0.00102	0.00257	CcSEcCtD
Dalfampridine—Mental disorder—Epirubicin—urinary bladder cancer	0.00102	0.00256	CcSEcCtD
Dalfampridine—Rash—Cisplatin—urinary bladder cancer	0.00101	0.00255	CcSEcCtD
Dalfampridine—Dermatitis—Cisplatin—urinary bladder cancer	0.00101	0.00254	CcSEcCtD
Dalfampridine—Nausea—Fluorouracil—urinary bladder cancer	0.001	0.00253	CcSEcCtD
Dalfampridine—Back pain—Epirubicin—urinary bladder cancer	0.000976	0.00246	CcSEcCtD
Dalfampridine—Angiopathy—Doxorubicin—urinary bladder cancer	0.000973	0.00245	CcSEcCtD
Dalfampridine—Dizziness—Etoposide—urinary bladder cancer	0.000971	0.00245	CcSEcCtD
Dalfampridine—Immune system disorder—Doxorubicin—urinary bladder cancer	0.000969	0.00244	CcSEcCtD
Dalfampridine—Mediastinal disorder—Doxorubicin—urinary bladder cancer	0.000967	0.00243	CcSEcCtD
Dalfampridine—Nausea—Cisplatin—urinary bladder cancer	0.000952	0.0024	CcSEcCtD
Dalfampridine—Mental disorder—Doxorubicin—urinary bladder cancer	0.00094	0.00237	CcSEcCtD
Dalfampridine—Convulsion—Methotrexate—urinary bladder cancer	0.000934	0.00235	CcSEcCtD
Dalfampridine—Vomiting—Etoposide—urinary bladder cancer	0.000934	0.00235	CcSEcCtD
Dalfampridine—Rash—Etoposide—urinary bladder cancer	0.000926	0.00233	CcSEcCtD
Dalfampridine—Dermatitis—Etoposide—urinary bladder cancer	0.000925	0.00233	CcSEcCtD
Dalfampridine—Headache—Etoposide—urinary bladder cancer	0.00092	0.00232	CcSEcCtD
Dalfampridine—Chest pain—Methotrexate—urinary bladder cancer	0.000918	0.00231	CcSEcCtD
Dalfampridine—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—urinary bladder cancer	0.000912	0.0023	CcSEcCtD
Dalfampridine—Back pain—Doxorubicin—urinary bladder cancer	0.000903	0.00227	CcSEcCtD
Dalfampridine—Confusional state—Methotrexate—urinary bladder cancer	0.000887	0.00223	CcSEcCtD
Dalfampridine—Anaphylactic shock—Methotrexate—urinary bladder cancer	0.00088	0.00222	CcSEcCtD
Dalfampridine—Convulsion—Epirubicin—urinary bladder cancer	0.000874	0.0022	CcSEcCtD
Dalfampridine—Infection—Methotrexate—urinary bladder cancer	0.000874	0.0022	CcSEcCtD
Dalfampridine—Nausea—Etoposide—urinary bladder cancer	0.000873	0.0022	CcSEcCtD
Dalfampridine—Nervous system disorder—Methotrexate—urinary bladder cancer	0.000863	0.00217	CcSEcCtD
Dalfampridine—Chest pain—Epirubicin—urinary bladder cancer	0.000859	0.00216	CcSEcCtD
Dalfampridine—Anxiety—Epirubicin—urinary bladder cancer	0.000856	0.00216	CcSEcCtD
Dalfampridine—Skin disorder—Methotrexate—urinary bladder cancer	0.000855	0.00215	CcSEcCtD
Dalfampridine—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—urinary bladder cancer	0.000853	0.00215	CcSEcCtD
Dalfampridine—Confusional state—Epirubicin—urinary bladder cancer	0.00083	0.00209	CcSEcCtD
Dalfampridine—Anaphylactic shock—Epirubicin—urinary bladder cancer	0.000823	0.00207	CcSEcCtD
Dalfampridine—Hypotension—Methotrexate—urinary bladder cancer	0.000822	0.00207	CcSEcCtD
Dalfampridine—Infection—Epirubicin—urinary bladder cancer	0.000818	0.00206	CcSEcCtD
Dalfampridine—Convulsion—Doxorubicin—urinary bladder cancer	0.000809	0.00204	CcSEcCtD
Dalfampridine—Nervous system disorder—Epirubicin—urinary bladder cancer	0.000808	0.00203	CcSEcCtD
Dalfampridine—Skin disorder—Epirubicin—urinary bladder cancer	0.0008	0.00201	CcSEcCtD
Dalfampridine—Insomnia—Methotrexate—urinary bladder cancer	0.000796	0.002	CcSEcCtD
Dalfampridine—Chest pain—Doxorubicin—urinary bladder cancer	0.000795	0.002	CcSEcCtD
Dalfampridine—Anxiety—Doxorubicin—urinary bladder cancer	0.000792	0.00199	CcSEcCtD
Dalfampridine—Paraesthesia—Methotrexate—urinary bladder cancer	0.00079	0.00199	CcSEcCtD
Dalfampridine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—urinary bladder cancer	0.000789	0.00199	CcSEcCtD
Dalfampridine—Dyspnoea—Methotrexate—urinary bladder cancer	0.000784	0.00198	CcSEcCtD
Dalfampridine—Dyspepsia—Methotrexate—urinary bladder cancer	0.000775	0.00195	CcSEcCtD
Dalfampridine—Hypotension—Epirubicin—urinary bladder cancer	0.000769	0.00194	CcSEcCtD
Dalfampridine—Confusional state—Doxorubicin—urinary bladder cancer	0.000768	0.00193	CcSEcCtD
Dalfampridine—Anaphylactic shock—Doxorubicin—urinary bladder cancer	0.000762	0.00192	CcSEcCtD
Dalfampridine—Gastrointestinal disorder—Methotrexate—urinary bladder cancer	0.00076	0.00191	CcSEcCtD
Dalfampridine—Infection—Doxorubicin—urinary bladder cancer	0.000757	0.00191	CcSEcCtD
Dalfampridine—Nervous system disorder—Doxorubicin—urinary bladder cancer	0.000747	0.00188	CcSEcCtD
Dalfampridine—Insomnia—Epirubicin—urinary bladder cancer	0.000745	0.00188	CcSEcCtD
Dalfampridine—Skin disorder—Doxorubicin—urinary bladder cancer	0.00074	0.00186	CcSEcCtD
Dalfampridine—Paraesthesia—Epirubicin—urinary bladder cancer	0.000739	0.00186	CcSEcCtD
Dalfampridine—Dyspnoea—Epirubicin—urinary bladder cancer	0.000734	0.00185	CcSEcCtD
Dalfampridine—Feeling abnormal—Methotrexate—urinary bladder cancer	0.000725	0.00183	CcSEcCtD
Dalfampridine—Dyspepsia—Epirubicin—urinary bladder cancer	0.000725	0.00183	CcSEcCtD
Dalfampridine—Hypotension—Doxorubicin—urinary bladder cancer	0.000712	0.00179	CcSEcCtD
Dalfampridine—Gastrointestinal disorder—Epirubicin—urinary bladder cancer	0.000711	0.00179	CcSEcCtD
Dalfampridine—Constipation—Epirubicin—urinary bladder cancer	0.000704	0.00177	CcSEcCtD
Dalfampridine—Urticaria—Methotrexate—urinary bladder cancer	0.000699	0.00176	CcSEcCtD
Dalfampridine—Insomnia—Doxorubicin—urinary bladder cancer	0.000689	0.00174	CcSEcCtD
Dalfampridine—Paraesthesia—Doxorubicin—urinary bladder cancer	0.000684	0.00172	CcSEcCtD
Dalfampridine—Dyspnoea—Doxorubicin—urinary bladder cancer	0.000679	0.00171	CcSEcCtD
Dalfampridine—Feeling abnormal—Epirubicin—urinary bladder cancer	0.000679	0.00171	CcSEcCtD
Dalfampridine—Dyspepsia—Doxorubicin—urinary bladder cancer	0.000671	0.00169	CcSEcCtD
Dalfampridine—Gastrointestinal disorder—Doxorubicin—urinary bladder cancer	0.000658	0.00166	CcSEcCtD
Dalfampridine—Urticaria—Epirubicin—urinary bladder cancer	0.000654	0.00165	CcSEcCtD
Dalfampridine—Constipation—Doxorubicin—urinary bladder cancer	0.000652	0.00164	CcSEcCtD
Dalfampridine—Hypersensitivity—Methotrexate—urinary bladder cancer	0.000648	0.00163	CcSEcCtD
Dalfampridine—Asthenia—Methotrexate—urinary bladder cancer	0.000631	0.00159	CcSEcCtD
Dalfampridine—Feeling abnormal—Doxorubicin—urinary bladder cancer	0.000628	0.00158	CcSEcCtD
Dalfampridine—Hypersensitivity—Epirubicin—urinary bladder cancer	0.000607	0.00153	CcSEcCtD
Dalfampridine—Urticaria—Doxorubicin—urinary bladder cancer	0.000605	0.00152	CcSEcCtD
Dalfampridine—Asthenia—Epirubicin—urinary bladder cancer	0.000591	0.00149	CcSEcCtD
Dalfampridine—Dizziness—Methotrexate—urinary bladder cancer	0.000582	0.00147	CcSEcCtD
Dalfampridine—Hypersensitivity—Doxorubicin—urinary bladder cancer	0.000561	0.00141	CcSEcCtD
Dalfampridine—Vomiting—Methotrexate—urinary bladder cancer	0.000559	0.00141	CcSEcCtD
Dalfampridine—Rash—Methotrexate—urinary bladder cancer	0.000555	0.0014	CcSEcCtD
Dalfampridine—Dermatitis—Methotrexate—urinary bladder cancer	0.000554	0.0014	CcSEcCtD
Dalfampridine—Headache—Methotrexate—urinary bladder cancer	0.000551	0.00139	CcSEcCtD
Dalfampridine—Asthenia—Doxorubicin—urinary bladder cancer	0.000547	0.00138	CcSEcCtD
Dalfampridine—Dizziness—Epirubicin—urinary bladder cancer	0.000545	0.00137	CcSEcCtD
Dalfampridine—Vomiting—Epirubicin—urinary bladder cancer	0.000524	0.00132	CcSEcCtD
Dalfampridine—Nausea—Methotrexate—urinary bladder cancer	0.000523	0.00132	CcSEcCtD
Dalfampridine—Rash—Epirubicin—urinary bladder cancer	0.000519	0.00131	CcSEcCtD
Dalfampridine—Dermatitis—Epirubicin—urinary bladder cancer	0.000519	0.00131	CcSEcCtD
Dalfampridine—Headache—Epirubicin—urinary bladder cancer	0.000516	0.0013	CcSEcCtD
Dalfampridine—Dizziness—Doxorubicin—urinary bladder cancer	0.000504	0.00127	CcSEcCtD
Dalfampridine—Nausea—Epirubicin—urinary bladder cancer	0.000489	0.00123	CcSEcCtD
Dalfampridine—Vomiting—Doxorubicin—urinary bladder cancer	0.000484	0.00122	CcSEcCtD
Dalfampridine—Rash—Doxorubicin—urinary bladder cancer	0.00048	0.00121	CcSEcCtD
Dalfampridine—Dermatitis—Doxorubicin—urinary bladder cancer	0.00048	0.00121	CcSEcCtD
Dalfampridine—Headache—Doxorubicin—urinary bladder cancer	0.000477	0.0012	CcSEcCtD
Dalfampridine—Nausea—Doxorubicin—urinary bladder cancer	0.000453	0.00114	CcSEcCtD
Dalfampridine—KCNQ1—SIDS Susceptibility Pathways—CREBBP—urinary bladder cancer	0.000234	0.00543	CbGpPWpGaD
Dalfampridine—KCNG2—Metabolism—NAT1—urinary bladder cancer	0.000229	0.00531	CbGpPWpGaD
Dalfampridine—KCNC2—Metabolism—NAT1—urinary bladder cancer	0.000229	0.00531	CbGpPWpGaD
Dalfampridine—KCNB1—Metabolism—GSTZ1—urinary bladder cancer	0.000229	0.00531	CbGpPWpGaD
Dalfampridine—KCNS3—Metabolism—NAT1—urinary bladder cancer	0.000229	0.00531	CbGpPWpGaD
Dalfampridine—KCNS3—Metabolism—GSTO2—urinary bladder cancer	0.000229	0.00531	CbGpPWpGaD
Dalfampridine—KCNG2—Metabolism—GSTO2—urinary bladder cancer	0.000229	0.00531	CbGpPWpGaD
Dalfampridine—KCNC2—Metabolism—GSTO2—urinary bladder cancer	0.000229	0.00531	CbGpPWpGaD
Dalfampridine—KCND2—Circadian rythm related genes—CDK4—urinary bladder cancer	0.000219	0.00508	CbGpPWpGaD
Dalfampridine—KCNH7—Circadian rythm related genes—FAS—urinary bladder cancer	0.000217	0.00504	CbGpPWpGaD
Dalfampridine—KCNB1—Metabolism—GSTO2—urinary bladder cancer	0.000217	0.00504	CbGpPWpGaD
Dalfampridine—KCNB1—Metabolism—NAT1—urinary bladder cancer	0.000217	0.00504	CbGpPWpGaD
Dalfampridine—KCNC2—Metabolism—UGT2B7—urinary bladder cancer	0.000209	0.00486	CbGpPWpGaD
Dalfampridine—KCNS3—Metabolism—UGT2B7—urinary bladder cancer	0.000209	0.00486	CbGpPWpGaD
Dalfampridine—KCNG2—Metabolism—UGT2B7—urinary bladder cancer	0.000209	0.00486	CbGpPWpGaD
Dalfampridine—CYP2E1—Biological oxidations—GSTZ1—urinary bladder cancer	0.000205	0.00476	CbGpPWpGaD
Dalfampridine—CYP2E1—Metapathway biotransformation—GSTZ1—urinary bladder cancer	0.000202	0.0047	CbGpPWpGaD
Dalfampridine—KCND2—Circadian rythm related genes—PPARG—urinary bladder cancer	0.000199	0.00461	CbGpPWpGaD
Dalfampridine—KCNB1—Metabolism—UGT2B7—urinary bladder cancer	0.000199	0.00461	CbGpPWpGaD
Dalfampridine—CYP2E1—Biological oxidations—GSTO2—urinary bladder cancer	0.000195	0.00451	CbGpPWpGaD
Dalfampridine—CYP2E1—Biological oxidations—NAT1—urinary bladder cancer	0.000195	0.00451	CbGpPWpGaD
Dalfampridine—CYP2E1—Metapathway biotransformation—GSTO2—urinary bladder cancer	0.000192	0.00445	CbGpPWpGaD
Dalfampridine—KCNH7—Circadian rythm related genes—CDK4—urinary bladder cancer	0.000191	0.00444	CbGpPWpGaD
Dalfampridine—KCNG2—Metabolism—CYP4B1—urinary bladder cancer	0.000189	0.00438	CbGpPWpGaD
Dalfampridine—KCNC2—Metabolism—CYP4B1—urinary bladder cancer	0.000189	0.00438	CbGpPWpGaD
Dalfampridine—KCNS3—Metabolism—CYP4B1—urinary bladder cancer	0.000189	0.00438	CbGpPWpGaD
Dalfampridine—KCNQ1—SIDS Susceptibility Pathways—CXCL8—urinary bladder cancer	0.000186	0.00431	CbGpPWpGaD
Dalfampridine—KCNB1—Metabolism—CYP4B1—urinary bladder cancer	0.000179	0.00415	CbGpPWpGaD
Dalfampridine—KCNC2—Metabolism—SLC19A1—urinary bladder cancer	0.000178	0.00413	CbGpPWpGaD
Dalfampridine—KCNG2—Metabolism—SLC19A1—urinary bladder cancer	0.000178	0.00413	CbGpPWpGaD
Dalfampridine—KCNS3—Metabolism—SLC19A1—urinary bladder cancer	0.000178	0.00413	CbGpPWpGaD
Dalfampridine—CYP2E1—Biological oxidations—UGT2B7—urinary bladder cancer	0.000178	0.00413	CbGpPWpGaD
Dalfampridine—CYP2E1—Metapathway biotransformation—UGT2B7—urinary bladder cancer	0.000176	0.00407	CbGpPWpGaD
Dalfampridine—KCNH7—Circadian rythm related genes—PPARG—urinary bladder cancer	0.000174	0.00403	CbGpPWpGaD
Dalfampridine—KCNG2—Metabolism—PRSS3—urinary bladder cancer	0.000174	0.00403	CbGpPWpGaD
Dalfampridine—KCNS3—Metabolism—PRSS3—urinary bladder cancer	0.000174	0.00403	CbGpPWpGaD
Dalfampridine—KCNC2—Metabolism—PRSS3—urinary bladder cancer	0.000174	0.00403	CbGpPWpGaD
Dalfampridine—KCNQ2—L1CAM interactions—SRC—urinary bladder cancer	0.00017	0.00394	CbGpPWpGaD
Dalfampridine—KCNQ3—L1CAM interactions—SRC—urinary bladder cancer	0.00017	0.00394	CbGpPWpGaD
Dalfampridine—KCNB1—Metabolism—SLC19A1—urinary bladder cancer	0.000169	0.00392	CbGpPWpGaD
Dalfampridine—KCNA3—BDNF signaling pathway—HRAS—urinary bladder cancer	0.000168	0.00389	CbGpPWpGaD
Dalfampridine—KCNB1—Metabolism—PRSS3—urinary bladder cancer	0.000165	0.00382	CbGpPWpGaD
Dalfampridine—KCNH2—SIDS Susceptibility Pathways—ESR2—urinary bladder cancer	0.000163	0.00378	CbGpPWpGaD
Dalfampridine—CYP2E1—Biological oxidations—CYP4B1—urinary bladder cancer	0.00016	0.00372	CbGpPWpGaD
Dalfampridine—KCNQ1—SIDS Susceptibility Pathways—EP300—urinary bladder cancer	0.000159	0.0037	CbGpPWpGaD
Dalfampridine—CYP2E1—Metapathway biotransformation—CYP4B1—urinary bladder cancer	0.000158	0.00367	CbGpPWpGaD
Dalfampridine—KCNQ2—L1CAM interactions—EGFR—urinary bladder cancer	0.000149	0.00345	CbGpPWpGaD
Dalfampridine—KCNQ3—L1CAM interactions—EGFR—urinary bladder cancer	0.000149	0.00345	CbGpPWpGaD
Dalfampridine—KCNG2—Metabolism—TYMP—urinary bladder cancer	0.000139	0.00322	CbGpPWpGaD
Dalfampridine—KCNS3—Metabolism—TYMP—urinary bladder cancer	0.000139	0.00322	CbGpPWpGaD
Dalfampridine—KCNC2—Metabolism—TYMP—urinary bladder cancer	0.000139	0.00322	CbGpPWpGaD
Dalfampridine—CYP2E1—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—urinary bladder cancer	0.000138	0.0032	CbGpPWpGaD
Dalfampridine—KCND2—Circadian rythm related genes—PTEN—urinary bladder cancer	0.000136	0.00316	CbGpPWpGaD
Dalfampridine—KCNB1—Metabolism—TYMP—urinary bladder cancer	0.000132	0.00305	CbGpPWpGaD
Dalfampridine—KCND2—Circadian rythm related genes—EP300—urinary bladder cancer	0.00013	0.00302	CbGpPWpGaD
Dalfampridine—KCNQ1—SIDS Susceptibility Pathways—TNF—urinary bladder cancer	0.000129	0.003	CbGpPWpGaD
Dalfampridine—KCNC2—Metabolism—NAT2—urinary bladder cancer	0.000125	0.00291	CbGpPWpGaD
Dalfampridine—KCNG2—Metabolism—NAT2—urinary bladder cancer	0.000125	0.00291	CbGpPWpGaD
Dalfampridine—KCNS3—Metabolism—NAT2—urinary bladder cancer	0.000125	0.00291	CbGpPWpGaD
Dalfampridine—KCNH7—Circadian rythm related genes—PTEN—urinary bladder cancer	0.000119	0.00277	CbGpPWpGaD
Dalfampridine—KCNB1—Metabolism—NAT2—urinary bladder cancer	0.000119	0.00276	CbGpPWpGaD
Dalfampridine—KCNH7—Circadian rythm related genes—EP300—urinary bladder cancer	0.000114	0.00264	CbGpPWpGaD
Dalfampridine—KCNA4—Neuronal System—HRAS—urinary bladder cancer	0.000111	0.00257	CbGpPWpGaD
Dalfampridine—KCNG4—Neuronal System—HRAS—urinary bladder cancer	0.000111	0.00257	CbGpPWpGaD
Dalfampridine—KCNH8—Neuronal System—HRAS—urinary bladder cancer	0.000111	0.00257	CbGpPWpGaD
Dalfampridine—KCNA5—Neuronal System—HRAS—urinary bladder cancer	0.000111	0.00257	CbGpPWpGaD
Dalfampridine—KCNS1—Neuronal System—HRAS—urinary bladder cancer	0.000111	0.00257	CbGpPWpGaD
Dalfampridine—KCNG3—Neuronal System—HRAS—urinary bladder cancer	0.000111	0.00257	CbGpPWpGaD
Dalfampridine—KCNC1—Neuronal System—HRAS—urinary bladder cancer	0.000111	0.00257	CbGpPWpGaD
Dalfampridine—KCNA6—Neuronal System—HRAS—urinary bladder cancer	0.000111	0.00257	CbGpPWpGaD
Dalfampridine—KCNS2—Neuronal System—HRAS—urinary bladder cancer	0.000111	0.00257	CbGpPWpGaD
Dalfampridine—KCNA10—Neuronal System—HRAS—urinary bladder cancer	0.000111	0.00257	CbGpPWpGaD
Dalfampridine—KCNG1—Neuronal System—HRAS—urinary bladder cancer	0.000111	0.00257	CbGpPWpGaD
Dalfampridine—KCND1—Neuronal System—HRAS—urinary bladder cancer	0.000111	0.00257	CbGpPWpGaD
Dalfampridine—KCNC4—Neuronal System—HRAS—urinary bladder cancer	0.000111	0.00257	CbGpPWpGaD
Dalfampridine—KCNH5—Neuronal System—HRAS—urinary bladder cancer	0.000111	0.00257	CbGpPWpGaD
Dalfampridine—KCNA2—Neuronal System—HRAS—urinary bladder cancer	0.000111	0.00257	CbGpPWpGaD
Dalfampridine—KCNH3—Neuronal System—HRAS—urinary bladder cancer	0.000111	0.00257	CbGpPWpGaD
Dalfampridine—KCNH1—Neuronal System—HRAS—urinary bladder cancer	0.000111	0.00257	CbGpPWpGaD
Dalfampridine—KCNV2—Neuronal System—HRAS—urinary bladder cancer	0.000111	0.00257	CbGpPWpGaD
Dalfampridine—KCNF1—Neuronal System—HRAS—urinary bladder cancer	0.000111	0.00257	CbGpPWpGaD
Dalfampridine—KCNB2—Neuronal System—HRAS—urinary bladder cancer	0.000111	0.00257	CbGpPWpGaD
Dalfampridine—KCNC3—Neuronal System—HRAS—urinary bladder cancer	0.000111	0.00257	CbGpPWpGaD
Dalfampridine—KCNV1—Neuronal System—HRAS—urinary bladder cancer	0.000111	0.00257	CbGpPWpGaD
Dalfampridine—KCNA7—Neuronal System—HRAS—urinary bladder cancer	0.000111	0.00257	CbGpPWpGaD
Dalfampridine—KCNH4—Neuronal System—HRAS—urinary bladder cancer	0.000111	0.00257	CbGpPWpGaD
Dalfampridine—KCNG2—Metabolism—RRM2—urinary bladder cancer	0.000108	0.00251	CbGpPWpGaD
Dalfampridine—KCNS3—Metabolism—RRM2—urinary bladder cancer	0.000108	0.00251	CbGpPWpGaD
Dalfampridine—KCNC2—Metabolism—RRM2—urinary bladder cancer	0.000108	0.00251	CbGpPWpGaD
Dalfampridine—CYP2E1—Biological oxidations—NAT2—urinary bladder cancer	0.000107	0.00247	CbGpPWpGaD
Dalfampridine—CYP2E1—Metapathway biotransformation—NAT2—urinary bladder cancer	0.000105	0.00244	CbGpPWpGaD
Dalfampridine—KCNB1—Metabolism—RRM2—urinary bladder cancer	0.000103	0.00238	CbGpPWpGaD
Dalfampridine—KCNQ3—Developmental Biology—NCOR1—urinary bladder cancer	0.0001	0.00233	CbGpPWpGaD
Dalfampridine—KCNQ2—Developmental Biology—NCOR1—urinary bladder cancer	0.0001	0.00233	CbGpPWpGaD
Dalfampridine—KCNG2—Metabolism—ENO2—urinary bladder cancer	0.0001	0.00233	CbGpPWpGaD
Dalfampridine—KCNS3—Metabolism—ENO2—urinary bladder cancer	0.0001	0.00233	CbGpPWpGaD
Dalfampridine—KCNC2—Metabolism—HPGDS—urinary bladder cancer	0.0001	0.00233	CbGpPWpGaD
Dalfampridine—KCNG2—Metabolism—HPGDS—urinary bladder cancer	0.0001	0.00233	CbGpPWpGaD
Dalfampridine—KCNC2—Metabolism—ENO2—urinary bladder cancer	0.0001	0.00233	CbGpPWpGaD
Dalfampridine—KCNS3—Metabolism—HPGDS—urinary bladder cancer	0.0001	0.00233	CbGpPWpGaD
Dalfampridine—KCNA3—Neuronal System—HRAS—urinary bladder cancer	9.88e-05	0.00229	CbGpPWpGaD
Dalfampridine—KCNG2—Metabolism—GSTT1—urinary bladder cancer	9.73e-05	0.00226	CbGpPWpGaD
Dalfampridine—KCNC2—Metabolism—GSTT1—urinary bladder cancer	9.73e-05	0.00226	CbGpPWpGaD
Dalfampridine—KCNS3—Metabolism—GSTT1—urinary bladder cancer	9.73e-05	0.00226	CbGpPWpGaD
Dalfampridine—KCNB1—Metabolism—ENO2—urinary bladder cancer	9.51e-05	0.00221	CbGpPWpGaD
Dalfampridine—KCNB1—Metabolism—HPGDS—urinary bladder cancer	9.51e-05	0.00221	CbGpPWpGaD
Dalfampridine—KCNQ4—Neuronal System—HRAS—urinary bladder cancer	9.42e-05	0.00219	CbGpPWpGaD
Dalfampridine—KCNQ5—Neuronal System—HRAS—urinary bladder cancer	9.42e-05	0.00219	CbGpPWpGaD
Dalfampridine—KCND2—Circadian rythm related genes—TP53—urinary bladder cancer	9.31e-05	0.00216	CbGpPWpGaD
Dalfampridine—KCNB1—Metabolism—GSTT1—urinary bladder cancer	9.22e-05	0.00214	CbGpPWpGaD
Dalfampridine—KCNQ2—Axon guidance—RHOA—urinary bladder cancer	8.76e-05	0.00203	CbGpPWpGaD
Dalfampridine—KCNQ3—Axon guidance—RHOA—urinary bladder cancer	8.76e-05	0.00203	CbGpPWpGaD
Dalfampridine—KCNH2—SIDS Susceptibility Pathways—CREBBP—urinary bladder cancer	8.66e-05	0.00201	CbGpPWpGaD
Dalfampridine—CYP2E1—Biological oxidations—HPGDS—urinary bladder cancer	8.52e-05	0.00198	CbGpPWpGaD
Dalfampridine—CYP2E1—Biological oxidations—GSTT1—urinary bladder cancer	8.27e-05	0.00192	CbGpPWpGaD
Dalfampridine—KCNH7—Circadian rythm related genes—TP53—urinary bladder cancer	8.14e-05	0.00189	CbGpPWpGaD
Dalfampridine—KCNQ2—Axon guidance—ERBB2—urinary bladder cancer	8.11e-05	0.00188	CbGpPWpGaD
Dalfampridine—KCNQ3—Axon guidance—ERBB2—urinary bladder cancer	8.11e-05	0.00188	CbGpPWpGaD
Dalfampridine—KCNS3—Metabolism—NQO1—urinary bladder cancer	8.09e-05	0.00188	CbGpPWpGaD
Dalfampridine—KCNC2—Metabolism—NQO1—urinary bladder cancer	8.09e-05	0.00188	CbGpPWpGaD
Dalfampridine—KCNG2—Metabolism—NQO1—urinary bladder cancer	8.09e-05	0.00188	CbGpPWpGaD
Dalfampridine—KCNQ2—Developmental Biology—CDK4—urinary bladder cancer	7.92e-05	0.00184	CbGpPWpGaD
Dalfampridine—KCNQ3—Developmental Biology—CDK4—urinary bladder cancer	7.92e-05	0.00184	CbGpPWpGaD
Dalfampridine—KCNG2—Neuronal System—HRAS—urinary bladder cancer	7.9e-05	0.00183	CbGpPWpGaD
Dalfampridine—KCNC2—Neuronal System—HRAS—urinary bladder cancer	7.9e-05	0.00183	CbGpPWpGaD
Dalfampridine—KCNS3—Neuronal System—HRAS—urinary bladder cancer	7.9e-05	0.00183	CbGpPWpGaD
Dalfampridine—KCND3—Neuronal System—HRAS—urinary bladder cancer	7.68e-05	0.00178	CbGpPWpGaD
Dalfampridine—KCNB1—Metabolism—NQO1—urinary bladder cancer	7.67e-05	0.00178	CbGpPWpGaD
Dalfampridine—KCNB1—Neuronal System—HRAS—urinary bladder cancer	7.49e-05	0.00174	CbGpPWpGaD
Dalfampridine—KCNQ2—Developmental Biology—PPARG—urinary bladder cancer	7.2e-05	0.00167	CbGpPWpGaD
Dalfampridine—KCNQ3—Developmental Biology—PPARG—urinary bladder cancer	7.2e-05	0.00167	CbGpPWpGaD
Dalfampridine—KCNQ3—Axon guidance—MMP9—urinary bladder cancer	6.96e-05	0.00161	CbGpPWpGaD
Dalfampridine—KCNQ2—Axon guidance—MMP9—urinary bladder cancer	6.96e-05	0.00161	CbGpPWpGaD
Dalfampridine—KCNQ2—Developmental Biology—CREBBP—urinary bladder cancer	6.91e-05	0.0016	CbGpPWpGaD
Dalfampridine—KCNQ3—Developmental Biology—CREBBP—urinary bladder cancer	6.91e-05	0.0016	CbGpPWpGaD
Dalfampridine—KCNH2—SIDS Susceptibility Pathways—CXCL8—urinary bladder cancer	6.87e-05	0.0016	CbGpPWpGaD
Dalfampridine—KCND2—Neuronal System—HRAS—urinary bladder cancer	6.85e-05	0.00159	CbGpPWpGaD
Dalfampridine—KCNQ1—Neuronal System—HRAS—urinary bladder cancer	6.85e-05	0.00159	CbGpPWpGaD
Dalfampridine—KCNG2—Metabolism—GSTP1—urinary bladder cancer	6.74e-05	0.00156	CbGpPWpGaD
Dalfampridine—KCNC2—Metabolism—GSTP1—urinary bladder cancer	6.74e-05	0.00156	CbGpPWpGaD
Dalfampridine—KCNS3—Metabolism—GSTP1—urinary bladder cancer	6.74e-05	0.00156	CbGpPWpGaD
Dalfampridine—KCNH6—Neuronal System—HRAS—urinary bladder cancer	6.71e-05	0.00156	CbGpPWpGaD
Dalfampridine—KCNQ2—Axon guidance—SRC—urinary bladder cancer	6.42e-05	0.00149	CbGpPWpGaD
Dalfampridine—KCNQ3—Axon guidance—SRC—urinary bladder cancer	6.42e-05	0.00149	CbGpPWpGaD
Dalfampridine—KCNB1—Metabolism—GSTP1—urinary bladder cancer	6.39e-05	0.00148	CbGpPWpGaD
Dalfampridine—KCNS3—Metabolism—TYMS—urinary bladder cancer	6.27e-05	0.00145	CbGpPWpGaD
Dalfampridine—KCNC2—Metabolism—TYMS—urinary bladder cancer	6.27e-05	0.00145	CbGpPWpGaD
Dalfampridine—KCNG2—Metabolism—TYMS—urinary bladder cancer	6.27e-05	0.00145	CbGpPWpGaD
Dalfampridine—KCNQ3—Developmental Biology—RHOA—urinary bladder cancer	6.25e-05	0.00145	CbGpPWpGaD
Dalfampridine—KCNQ2—Developmental Biology—RHOA—urinary bladder cancer	6.25e-05	0.00145	CbGpPWpGaD
Dalfampridine—KCNC2—Metabolism—NCOR1—urinary bladder cancer	6.2e-05	0.00144	CbGpPWpGaD
Dalfampridine—KCNS3—Metabolism—GSTM1—urinary bladder cancer	6.2e-05	0.00144	CbGpPWpGaD
Dalfampridine—KCNG2—Metabolism—GSTM1—urinary bladder cancer	6.2e-05	0.00144	CbGpPWpGaD
Dalfampridine—KCNC2—Metabolism—GSTM1—urinary bladder cancer	6.2e-05	0.00144	CbGpPWpGaD
Dalfampridine—KCNS3—Metabolism—NCOR1—urinary bladder cancer	6.2e-05	0.00144	CbGpPWpGaD
Dalfampridine—KCNG2—Metabolism—NCOR1—urinary bladder cancer	6.2e-05	0.00144	CbGpPWpGaD
Dalfampridine—KCNA1—Neuronal System—HRAS—urinary bladder cancer	6.07e-05	0.00141	CbGpPWpGaD
Dalfampridine—KCNH7—Neuronal System—HRAS—urinary bladder cancer	5.98e-05	0.00139	CbGpPWpGaD
Dalfampridine—KCNB1—Metabolism—TYMS—urinary bladder cancer	5.94e-05	0.00138	CbGpPWpGaD
Dalfampridine—KCNG2—Metabolism—GPX1—urinary bladder cancer	5.93e-05	0.00138	CbGpPWpGaD
Dalfampridine—KCNS3—Metabolism—GPX1—urinary bladder cancer	5.93e-05	0.00138	CbGpPWpGaD
Dalfampridine—KCNC2—Metabolism—GPX1—urinary bladder cancer	5.93e-05	0.00138	CbGpPWpGaD
Dalfampridine—KCNH2—SIDS Susceptibility Pathways—EP300—urinary bladder cancer	5.9e-05	0.00137	CbGpPWpGaD
Dalfampridine—KCNB1—Metabolism—GSTM1—urinary bladder cancer	5.87e-05	0.00136	CbGpPWpGaD
Dalfampridine—KCNB1—Metabolism—NCOR1—urinary bladder cancer	5.87e-05	0.00136	CbGpPWpGaD
Dalfampridine—KCNC2—Metabolism—ERCC2—urinary bladder cancer	5.83e-05	0.00135	CbGpPWpGaD
Dalfampridine—KCNS3—Metabolism—ERCC2—urinary bladder cancer	5.83e-05	0.00135	CbGpPWpGaD
Dalfampridine—KCNG2—Metabolism—ERCC2—urinary bladder cancer	5.83e-05	0.00135	CbGpPWpGaD
Dalfampridine—KCNQ3—Developmental Biology—ERBB2—urinary bladder cancer	5.79e-05	0.00134	CbGpPWpGaD
Dalfampridine—KCNQ2—Developmental Biology—ERBB2—urinary bladder cancer	5.79e-05	0.00134	CbGpPWpGaD
Dalfampridine—CYP2E1—Biological oxidations—GSTP1—urinary bladder cancer	5.73e-05	0.00133	CbGpPWpGaD
Dalfampridine—CYP2E1—Metapathway biotransformation—GSTP1—urinary bladder cancer	5.65e-05	0.00131	CbGpPWpGaD
Dalfampridine—KCNB1—Metabolism—GPX1—urinary bladder cancer	5.63e-05	0.00131	CbGpPWpGaD
Dalfampridine—KCNQ2—Axon guidance—EGFR—urinary bladder cancer	5.62e-05	0.0013	CbGpPWpGaD
Dalfampridine—KCNQ3—Axon guidance—EGFR—urinary bladder cancer	5.62e-05	0.0013	CbGpPWpGaD
Dalfampridine—KCNB1—Metabolism—ERCC2—urinary bladder cancer	5.52e-05	0.00128	CbGpPWpGaD
Dalfampridine—KCNS3—Metabolism—MTHFR—urinary bladder cancer	5.48e-05	0.00127	CbGpPWpGaD
Dalfampridine—KCNG2—Metabolism—MTHFR—urinary bladder cancer	5.48e-05	0.00127	CbGpPWpGaD
Dalfampridine—KCNC2—Metabolism—MTHFR—urinary bladder cancer	5.48e-05	0.00127	CbGpPWpGaD
Dalfampridine—KCNQ3—Axon guidance—KRAS—urinary bladder cancer	5.31e-05	0.00123	CbGpPWpGaD
Dalfampridine—KCNQ2—Axon guidance—KRAS—urinary bladder cancer	5.31e-05	0.00123	CbGpPWpGaD
Dalfampridine—CYP2E1—Biological oxidations—GSTM1—urinary bladder cancer	5.27e-05	0.00122	CbGpPWpGaD
Dalfampridine—CYP2E1—Metapathway biotransformation—GSTM1—urinary bladder cancer	5.19e-05	0.0012	CbGpPWpGaD
Dalfampridine—KCNB1—Metabolism—MTHFR—urinary bladder cancer	5.19e-05	0.0012	CbGpPWpGaD
Dalfampridine—KCNQ2—Neuronal System—HRAS—urinary bladder cancer	5.09e-05	0.00118	CbGpPWpGaD
Dalfampridine—KCNQ3—Neuronal System—HRAS—urinary bladder cancer	5.09e-05	0.00118	CbGpPWpGaD
Dalfampridine—KCNQ3—Developmental Biology—MMP9—urinary bladder cancer	4.97e-05	0.00115	CbGpPWpGaD
Dalfampridine—KCNQ2—Developmental Biology—MMP9—urinary bladder cancer	4.97e-05	0.00115	CbGpPWpGaD
Dalfampridine—KCNH2—SIDS Susceptibility Pathways—TNF—urinary bladder cancer	4.79e-05	0.00111	CbGpPWpGaD
Dalfampridine—KCNQ3—Developmental Biology—EP300—urinary bladder cancer	4.71e-05	0.00109	CbGpPWpGaD
Dalfampridine—KCNQ2—Developmental Biology—EP300—urinary bladder cancer	4.71e-05	0.00109	CbGpPWpGaD
Dalfampridine—KCNQ3—Developmental Biology—SRC—urinary bladder cancer	4.58e-05	0.00106	CbGpPWpGaD
Dalfampridine—KCNQ2—Developmental Biology—SRC—urinary bladder cancer	4.58e-05	0.00106	CbGpPWpGaD
Dalfampridine—KCNQ2—Axon guidance—HRAS—urinary bladder cancer	4.52e-05	0.00105	CbGpPWpGaD
Dalfampridine—KCNQ3—Axon guidance—HRAS—urinary bladder cancer	4.52e-05	0.00105	CbGpPWpGaD
Dalfampridine—KCNS3—Metabolism—PPARG—urinary bladder cancer	4.44e-05	0.00103	CbGpPWpGaD
Dalfampridine—KCNG2—Metabolism—PPARG—urinary bladder cancer	4.44e-05	0.00103	CbGpPWpGaD
Dalfampridine—KCNC2—Metabolism—PPARG—urinary bladder cancer	4.44e-05	0.00103	CbGpPWpGaD
Dalfampridine—KCNC2—Metabolism—CREBBP—urinary bladder cancer	4.27e-05	0.00099	CbGpPWpGaD
Dalfampridine—KCNS3—Metabolism—CREBBP—urinary bladder cancer	4.27e-05	0.00099	CbGpPWpGaD
Dalfampridine—KCNG2—Metabolism—CREBBP—urinary bladder cancer	4.27e-05	0.00099	CbGpPWpGaD
Dalfampridine—KCNB1—Metabolism—PPARG—urinary bladder cancer	4.21e-05	0.000977	CbGpPWpGaD
Dalfampridine—KCNB1—Metabolism—CREBBP—urinary bladder cancer	4.04e-05	0.000939	CbGpPWpGaD
Dalfampridine—KCNQ2—Developmental Biology—EGFR—urinary bladder cancer	4.01e-05	0.000931	CbGpPWpGaD
Dalfampridine—KCNQ3—Developmental Biology—EGFR—urinary bladder cancer	4.01e-05	0.000931	CbGpPWpGaD
Dalfampridine—KCNQ3—Developmental Biology—TNF—urinary bladder cancer	3.82e-05	0.000887	CbGpPWpGaD
Dalfampridine—KCNQ2—Developmental Biology—TNF—urinary bladder cancer	3.82e-05	0.000887	CbGpPWpGaD
Dalfampridine—KCNQ3—Developmental Biology—KRAS—urinary bladder cancer	3.79e-05	0.00088	CbGpPWpGaD
Dalfampridine—KCNQ2—Developmental Biology—KRAS—urinary bladder cancer	3.79e-05	0.00088	CbGpPWpGaD
Dalfampridine—CYP2E1—Metabolism—GSTZ1—urinary bladder cancer	3.51e-05	0.000814	CbGpPWpGaD
Dalfampridine—KCNG2—Metabolism—PTGS2—urinary bladder cancer	3.49e-05	0.000811	CbGpPWpGaD
Dalfampridine—KCNC2—Metabolism—PTGS2—urinary bladder cancer	3.49e-05	0.000811	CbGpPWpGaD
Dalfampridine—KCNS3—Metabolism—PTGS2—urinary bladder cancer	3.49e-05	0.000811	CbGpPWpGaD
Dalfampridine—CYP2E1—Metabolism—GSTO2—urinary bladder cancer	3.33e-05	0.000772	CbGpPWpGaD
Dalfampridine—CYP2E1—Metabolism—NAT1—urinary bladder cancer	3.33e-05	0.000772	CbGpPWpGaD
Dalfampridine—KCNB1—Metabolism—PTGS2—urinary bladder cancer	3.31e-05	0.000769	CbGpPWpGaD
Dalfampridine—KCNQ2—Developmental Biology—HRAS—urinary bladder cancer	3.22e-05	0.000748	CbGpPWpGaD
Dalfampridine—KCNQ3—Developmental Biology—HRAS—urinary bladder cancer	3.22e-05	0.000748	CbGpPWpGaD
Dalfampridine—KCNG2—Metabolism—PTEN—urinary bladder cancer	3.05e-05	0.000707	CbGpPWpGaD
Dalfampridine—KCNS3—Metabolism—PTEN—urinary bladder cancer	3.05e-05	0.000707	CbGpPWpGaD
Dalfampridine—KCNC2—Metabolism—PTEN—urinary bladder cancer	3.05e-05	0.000707	CbGpPWpGaD
Dalfampridine—CYP2E1—Metabolism—UGT2B7—urinary bladder cancer	3.04e-05	0.000706	CbGpPWpGaD
Dalfampridine—KCNC2—Metabolism—EP300—urinary bladder cancer	2.91e-05	0.000674	CbGpPWpGaD
Dalfampridine—KCNS3—Metabolism—EP300—urinary bladder cancer	2.91e-05	0.000674	CbGpPWpGaD
Dalfampridine—KCNG2—Metabolism—EP300—urinary bladder cancer	2.91e-05	0.000674	CbGpPWpGaD
Dalfampridine—KCNB1—Metabolism—PTEN—urinary bladder cancer	2.89e-05	0.00067	CbGpPWpGaD
Dalfampridine—KCNB1—Metabolism—EP300—urinary bladder cancer	2.75e-05	0.000639	CbGpPWpGaD
Dalfampridine—CYP2E1—Metabolism—CYP4B1—urinary bladder cancer	2.74e-05	0.000636	CbGpPWpGaD
Dalfampridine—CYP2E1—Metabolism—SLC19A1—urinary bladder cancer	2.59e-05	0.0006	CbGpPWpGaD
Dalfampridine—KCNH2—Neuronal System—HRAS—urinary bladder cancer	2.53e-05	0.000588	CbGpPWpGaD
Dalfampridine—CYP2E1—Metabolism—PRSS3—urinary bladder cancer	2.52e-05	0.000585	CbGpPWpGaD
Dalfampridine—CYP2E1—Metabolism—TYMP—urinary bladder cancer	2.02e-05	0.000468	CbGpPWpGaD
Dalfampridine—CYP2E1—Metabolism—NAT2—urinary bladder cancer	1.82e-05	0.000423	CbGpPWpGaD
Dalfampridine—CYP2E1—Metabolism—RRM2—urinary bladder cancer	1.57e-05	0.000365	CbGpPWpGaD
Dalfampridine—CYP2E1—Metabolism—ENO2—urinary bladder cancer	1.46e-05	0.000338	CbGpPWpGaD
Dalfampridine—CYP2E1—Metabolism—HPGDS—urinary bladder cancer	1.46e-05	0.000338	CbGpPWpGaD
Dalfampridine—CYP2E1—Metabolism—GSTT1—urinary bladder cancer	1.41e-05	0.000328	CbGpPWpGaD
Dalfampridine—CYP2E1—Metabolism—NQO1—urinary bladder cancer	1.17e-05	0.000273	CbGpPWpGaD
Dalfampridine—CYP2E1—Metabolism—GSTP1—urinary bladder cancer	9.8e-06	0.000227	CbGpPWpGaD
Dalfampridine—CYP2E1—Metabolism—TYMS—urinary bladder cancer	9.11e-06	0.000211	CbGpPWpGaD
Dalfampridine—CYP2E1—Metabolism—GSTM1—urinary bladder cancer	9e-06	0.000209	CbGpPWpGaD
Dalfampridine—CYP2E1—Metabolism—NCOR1—urinary bladder cancer	9e-06	0.000209	CbGpPWpGaD
Dalfampridine—CYP2E1—Metabolism—GPX1—urinary bladder cancer	8.62e-06	0.0002	CbGpPWpGaD
Dalfampridine—CYP2E1—Metabolism—ERCC2—urinary bladder cancer	8.47e-06	0.000196	CbGpPWpGaD
Dalfampridine—CYP2E1—Metabolism—MTHFR—urinary bladder cancer	7.96e-06	0.000185	CbGpPWpGaD
Dalfampridine—CYP2E1—Metabolism—PPARG—urinary bladder cancer	6.45e-06	0.00015	CbGpPWpGaD
Dalfampridine—CYP2E1—Metabolism—CREBBP—urinary bladder cancer	6.2e-06	0.000144	CbGpPWpGaD
Dalfampridine—CYP2E1—Metabolism—PTGS2—urinary bladder cancer	5.08e-06	0.000118	CbGpPWpGaD
Dalfampridine—CYP2E1—Metabolism—PTEN—urinary bladder cancer	4.43e-06	0.000103	CbGpPWpGaD
Dalfampridine—CYP2E1—Metabolism—EP300—urinary bladder cancer	4.22e-06	9.8e-05	CbGpPWpGaD
